Health · Pharma & Biotech · 1 hr ago
Experimental injection reduced visceral fat by 12% in early trials
CBL-514 is an experimental injection tested in two phase 2 trials to reduce visceral fat, which lies deep in the abdomen around internal organs.
Participants received injections in their lower abdomen every three weeks for up to 12 weeks.
Four weeks after the final treatment, the average visceral fat volume in the CBL-514 group was 12.01% lower, while it was 5.68% higher in the placebo group.
Visceral fat affects metabolism and insulin resistance and can influence the development of type 2 diabetes.
Research published in March by the American Heart Association found a stronger association between visceral fat and heart failure risk than between BMI and that risk.
The results are early trial findings, and the sources do not say what happens next in testing.
An experimental injection called CBL-514 was associated with a 12.01% average reduction in visceral fat in early human trials.
Four weeks after the final treatment, participants who received a placebo had an average 5.68% increase in visceral fat.
Participants received injections in the lower abdomen every three weeks for up to 12 weeks, with doses of up to 600 milligrams.
The trials were conducted by Dr. W. Timothy Garvey of the University of Alabama at Birmingham and Yu-Fang Ling of Caliway Biopharmaceuticals.
- Who
- Participants in two phase 2 trials received CBL-514 or a placebo. The trials were conducted by Dr. W. Timothy Garvey and Yu-Fang Ling.
- What
- CBL-514 was associated with an average 12.01% reduction in visceral fat.
- When
- The results were measured four weeks after the final treatment. The article was published on 2026-10-11.
- Where
- In the lower abdomen, where participants received the injections. The trials’ locations are not stated.
- Why
- The trials tested whether CBL-514 could reduce visceral fat.
This story does not have two clearly opposing sides.
No direct quotes in the coverage so far.
Participants received lower-abdominal injections every three weeks for up to 12 weeks.
Average visceral fat volume was 12.01% lower in the CBL-514 group and 5.68% higher in the placebo group.
- Drug
- CBL-514
- Average change in visceral fat
- 12.01% decrease with CBL-514
- Placebo comparison
- 5.68% increase in visceral fat
- Treatment schedule
- Injections every three weeks for up to 12 weeks
- Maximum dose
- 600 milligrams
Sources
Related news
AstraZeneca blames trial design for failed bone disease drug study
Baby Sleep Gripe Water Recalled After Alcohol Found in Testing
FDA Warns Amazon Over Unapproved Herpes Treatments
Possible Wrong Dose Raises Questions for PDE9 Drug Trials in Heart Failure
FDA approves atezolizumab with chemotherapy for some stage III colon cancers
Review links drug company gifts to more and less appropriate prescribing
Brazil suspends Peptistrong supplement and orders all batches recalled
Experimental eye drops improve vision in a small study of a rare eye disease
Taboos limit sales of weight-loss drugs in India despite obesity rates
Roche reports year-long results for eye drug Vamikibart
